![Charles Frantzreb](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Frantzreb
Directeur/Membre du Conseil chez
VERRICA PHARMACEUTICALS INC.
Profil
Charles A. Frantzreb is Director at Verrica Pharmaceuticals, Inc. since 2025 and Partner at Caligan Partners LP since 2024.
Formerly, Research Analyst at Piper Sandler & Co. (Broker) from 2018 to 2020 and Senior Analyst at Great Point Partners LLC from 2023 to 2024.
Education includes an undergraduate degree from Cornell University conferred in 2011 and a doctorate from the University of Pennsylvania Medical Center conferred in 2017.
Postes actifs de Charles Frantzreb
| Sociétés | Poste | Début |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 26/12/2025 |
Caligan Partners LP
 Caligan Partners LP Investment ManagersFinance Caligan Partners seeks to identify companies it believes are undervalued, potentially because their sectors are out of favor or may be undergoing significant transition and where the firm believes its influence can act as a catalyst for a re-valuation of the investment or help to change the underlying performance of the investment, whether through financial or operational restructuring or a strategic repositioning or transaction. Their focus on undervalued securities is due to its belief that purchase price is the most important determinant of the success of an investment. | Analyst-Equity | 01/12/2024 |
Anciens postes connus de Charles Frantzreb
| Sociétés | Poste | Fin |
|---|---|---|
Great Point Partners LLC
 Great Point Partners LLC Investment ManagersFinance Great Point seeks to achieve positive excess returns by investing in publicly traded biotechnology, pharmaceutical and life science companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Their hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. Great Point Partners targets fast-growing, technology- driven small-cap companies. In addition, the firm manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies. | Analyst-Equity | 01/01/2024 |
Piper Sandler & Co. (Broker)
 Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/08/2020 |
Formation de Charles Frantzreb
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Great Point Partners LLC
Great Point Partners LLC Investment ManagersFinance Great Point seeks to achieve positive excess returns by investing in publicly traded biotechnology, pharmaceutical and life science companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Their hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. Great Point Partners targets fast-growing, technology- driven small-cap companies. In addition, the firm manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania Medical Center
 University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verrica Pharmaceuticals, Inc.
 Verrica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Caligan Partners LP
Caligan Partners LP Investment ManagersFinance Caligan Partners seeks to identify companies it believes are undervalued, potentially because their sectors are out of favor or may be undergoing significant transition and where the firm believes its influence can act as a catalyst for a re-valuation of the investment or help to change the underlying performance of the investment, whether through financial or operational restructuring or a strategic repositioning or transaction. Their focus on undervalued securities is due to its belief that purchase price is the most important determinant of the success of an investment. | Finance |
